- Poster presentation
- Open Access
Procalcitonin as a marker of bacterial sepsis in immunocompromised patients
Retrovirology volume 9, Article number: P90 (2012)
Procalcitonin (PCT) is a recently described marker of severe sepsis. It was decided to assess the value of PCT as a marker of secondary infection in patients infected with HIV in Georgian AIDS Center.
Materials and methods
PCT plasma levels were measured by quantitative assay BRAHMS-Biomérieux using the VIDAS analyser in a prospective study in 135 HIV-infected individuals: 87 asymptomatic and 48 with lever or suspected secondary infections.
The baseline plasma level of PCT was (0.5 ng/ml +/- 0.5), even in the latest stages of the disease, and did not differ from the values of healthy subjects (0.54 ng/ml +/- 0.1). EDTA-treated whole blood was collected from patients before starting specific antimicrobial therapy. No elevation of PCT level was detected in HIV-infected patients with evolving secondary infections including PCP (n = 4), cerebral toxoplasmosis (n = 5), viral infections (n = 9), mycobacterial infections (n = 4), localized bacterial (n = 13) and fungal infections (n = 4), and in various associated infectious and non-infectious febrile events (n = 15). All these plasma values were lower than 2 ng/ml. In contrast, high PCT plasma levels were detected in one HIV-infected patient with a septicaemic influenza infection (17 ng/ml) and another one with a septicaemic Pneudomonas aeruginosa infection (46 ng/ ml), PCT values decreased rapidly under appropriate therapy.
We found that PCT is a specific marker of bacterial sepsis in HIV-infected patients, as no increase in other secondary infections could be detected in those patients. A rapid determination of PCT level could be useful to verify or refute bacterial sepsis for a better management of febrile HIV-infected patients.
About this article
Cite this article
Gatserelia, L., Sharvadze, L., Karchava, M. et al. Procalcitonin as a marker of bacterial sepsis in immunocompromised patients. Retrovirology 9, P90 (2012) doi:10.1186/1742-4690-9-S1-P90
- Severe Sepsis
- Antimicrobial Therapy
- Secondary Infection